Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter study of zigakibart (FUB523) in adult IgA nephropathy
CTR20254930Phase 2Active
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of zigakibart in IgA nephropathy (IgAN), sponsored by Novartis. Started Jul 2026; status: active.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20254930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254930.